Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80199 |
Name | colorectal carcinoma |
Definition | A colorectal cancer that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colorectal carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
EML4 - ALK | Crizotinib | colorectal carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Lorlatinib | colorectal carcinoma | predicted - sensitive | detail... |
MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 | Nivolumab | colorectal carcinoma | predicted - sensitive | detail... |
BRAF V600E | Palbociclib + PD-0325901 | colorectal carcinoma | no benefit | detail... |
BRAF V600E | Gedatolisib + Palbociclib | colorectal carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03287427 | Phase I | TetMYB + Tislelizumab | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO) | Completed | AUS | 0 |
NCT03428958 | Phase I | A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Completed | USA | GBR | FRA | 0 | |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT04060407 | Phase Ib/II | CD24Fc + Ipilimumab + Nivolumab | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) | Withdrawn | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT04793958 | Phase III | Adagrasib + Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT04975256 | Phase I | Adagrasib + BI 1701963 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Completed | USA | 0 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |
NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Active, not recruiting | USA | SWE | SVK | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05700656 | Phase Ib/II | Capecitabine + Galunisertib | Galunisertib Combined With Capecitabine in Advanced CRC With PM | Recruiting | NLD | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Recruiting | USA | 0 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06216561 | Phase I | CEND-1 | Intraperitoneal LSTA1 in CRS-HIPEC | Withdrawn | USA | 0 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06462183 | Phase I | RGT-61159 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Recruiting | USA | CAN | 0 |